Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28874964 | 0.84 | LMNA (0.72) | HTTLMNAKDM4EMAPT | |
| SCHEMBL13779423 | 0.84 | LMNA (0.72) | HTTLMNAPOLBKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL5703006 | 0.83 | LMNA (0.70) | HTTLMNAPOLBKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL9618640 | 0.83 | LMNA (0.70) | HTTLMNAPOLBKDM4EMAPT | |
| SCHEMBL28868030 | 0.80 | KDM4E (1.00) | LMNAPOLBKDM4EMAOBMAPT | |
| SCHEMBL16224357 | 0.80 | LMNA (0.67) | HTTLMNAKDM4EMAPTNPSR1 | |
| Phenylthiosemicarbazone SCHEMBL674762 | 0.79 | KDM4E (0.81) | HTTLMNAPOLBKDM4EMAOB | |
| Phenylthiosemicarbazone SCHEMBL674761 | 0.79 | KDM4E (0.81) | HTTLMNAPOLBKDM4EMAOB | |
| SCHEMBL4122642 | 0.79 | ESR1 (0.65) | HTTLMNAKDM4EMAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL17560774 | 0.79 | LMNA (0.65) | HTTLMNAKDM4EMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006294-B2 | Therapeutic compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-06-11 | — | — | US | disclosed |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-10-31 | — | — | US | disclosed |
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330157-A1 | THERAPEUTIC COMPOUNDS | OPRL1, INA, OGFR | HTT 766/4885LMNA 1901/4885POLB 4376/4885 |
| US-12006294-B2 | Therapeutic compounds | OPRL1, INA, OGFR | HTT 766/4885LMNA 1901/4885POLB 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.